Literature DB >> 35112997

Tumour-suppressing functions of the lncRNA MBNL1-AS1/miR-889-3p/KLF9 axis in human breast cancer cells.

Yongmei Jin1, Lingli Xu2, Bin Zhao2, Wenqing Bao3, Ying Ye4, Yang Tong2, Qiyu Sun5, Jianping Liu2.   

Abstract

This study aimed to explore the role and potential mechanism of the long non-coding (lncRNA) MBNL1-AS1 in human breast cancer. We included 80 patients with breast cancer in this study. Breast cancer cell lines, including MCF7, SKBR3, MDA-MB-231 and MDA-MB-415, and the normal human breast cell line MCF10A were used in this study. MBNL1-AS1, miR-889-3p mimics, si-Krüppel-like factor 9 (KLF9) or their controls were transfected in the cells. Quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting and immunohistochemistry assay were performed to detect the expression of MBNL1-AS1, miR-889-3p and KLF9. Cell proliferation, invasion and migration were detected. Luciferase reporter gene and pull-down assay were performed to verify the target relationship among MBNL1-AS1, miR-889-3p and KLF9. Glycolysis was also detected after transfection. The expression of the lncRNA MBNL1-AS1 was low in the breast cancer tissues and cells. Lower expression levels of the lncRNA MBNL1-AS1 were associated with poor prognosis of breast cancer. Overexpression of the lncRNA MBNL1-AS1 decreased proliferation, invasion, migration and glycolysis of breast cancer cells. The lncRNA MBNL1-AS1 could interact with miR-889-3p, and KLF9 was the downstream target of miR-889-3p. Moreover, miR-889-3p was negatively correlated with KLF9 and lncRNA MBNL1-AS1. Both miR-889-3p and si-KLF9 could reverse the overexpression of lncRNA MBNL1-AS1 in breast cancer development. The lncRNA MBNL1-AS1 decreased proliferation, invasion, migration and glycolysis of breast cancer via the miR-889-3p/KLF9 axis, which might be a potential biomarker for the diagnosis of breast cancer.

Entities:  

Keywords:  Breast cancer; KLF9; lncRNA MBNL1-AS1; miR-889-3p

Mesh:

Substances:

Year:  2022        PMID: 35112997      PMCID: PMC9037535          DOI: 10.1080/15384101.2022.2034254

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  30 in total

1.  miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP.

Authors:  Yanting Xu; Jiangtu He; Yue Wang; Xinyi Zhu; Qiuhui Pan; Qiuling Xie; Fenyong Sun
Journal:  FEBS Lett       Date:  2015-04-01       Impact factor: 4.124

2.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

3.  KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma.

Authors:  Hanfeng Guan; Linka Xie; Frank Leithäuser; Lucia Flossbach; Peter Möller; Thomas Wirth; Alexey Ushmorov
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

Review 4.  Emerging players in prostate cancer: long non-coding RNAs.

Authors:  Tong Sun; Huihui Ye; Chin-Lee Wu; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  Am J Clin Exp Urol       Date:  2014-12-25

5.  LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway.

Authors:  C Xiao; C-H Wu; H-Z Hu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-07       Impact factor: 3.507

6.  Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes.

Authors:  Akhlaq Ahmad; Weijie Zhang; Mingming Wu; Sheng Tan; Tao Zhu
Journal:  Genes Genomics       Date:  2017-10-19       Impact factor: 1.839

7.  Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer.

Authors:  Hideaki Dote; Shinichi Toyooka; Kazunori Tsukuda; Masaaki Yano; Mamoru Ouchida; Hiroyoshi Doihara; Makoto Suzuki; Hong Chen; Jer-Tsong Hsieh; Adi F Gazdar; Nobuyoshi Shimizu
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

8.  miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10.

Authors:  Yating Chen; Jin Zhang; Huijun Wang; Jiayi Zhao; Cheng Xu; Yingying Du; Xin Luo; Fengyun Zheng; Rui Liu; Hongwei Zhang; Duan Ma
Journal:  BMC Cancer       Date:  2012-03-23       Impact factor: 4.430

9.  LncRNA MBNL1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer.

Authors:  Xiaosong Wei; Xiaoming Yang; Beibei Wang; Yang Yang; Zhiwei Fang; Chengzhi Yi; Lei Shi; Dongkui Song
Journal:  Cancer Med       Date:  2019-11-25       Impact factor: 4.452

10.  Retracted Article: Long non-coding RNA NEAT1 accelerates cell progression in cervical cancer by regulating the miR-889-3p/E2F7 axis through the activation of the PI3K/AKT pathway.

Authors:  Hongmei Zhou; Ruixia Guo; Chunfang Wang
Journal:  RSC Adv       Date:  2019-10-31       Impact factor: 4.036

View more
  3 in total

1.  Identification of miRNA biomarkers for breast cancer by combining ensemble regularized multinomial logistic regression and Cox regression.

Authors:  Juntao Li; Hongmei Zhang; Fugen Gao
Journal:  BMC Bioinformatics       Date:  2022-10-18       Impact factor: 3.307

2.  circIFITM1/miR-802/Foxp1 Axis Participates in Proliferation and Invasion of Lovo Cells.

Authors:  Yu Wan; Jinhua He; Zeping Han; Shengbo Wang; Yingying Zhao; Di Zeng; Ying Tang; Yiwei He; Lishan Zeng
Journal:  Dis Markers       Date:  2022-06-24       Impact factor: 3.464

3.  Circular RNA_0078767 upregulates Kruppel-like factor 9 expression by targeting microRNA-889, thereby inhibiting the progression of osteosarcoma.

Authors:  Qiu Chen; Haishen Zhou; Weihao Rong
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.